Systems vaccinology: Enabling rational vaccine design with systems biological approaches

Vaccine

Volumn 33, Issue 40, 2015, Pages 5294-5301

  Hagan, Thomas ^a   Nakaya, Helder I ^b,c   Subramaniam, Shankar ^a,d,e,f   Pulendran, Bali ^c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Systems biology; Systems vaccinology; Vaccines

Indexed keywords

VACCINE; TRANSCRIPTOME;

ADAPTIVE IMMUNITY; ARTICLE; BIOTECHNOLOGY; DRUG DESIGN; HISTORY OF MEDICINE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGIST; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; SYSTEMS BIOLOGY; SYSTEMS VACCINOLOGY; VACCINATION; ANIMAL; IMMUNOLOGY; INFORMATION PROCESSING; PROCEDURES;

ANIMALS; DATASETS AS TOPIC; HUMANS; SYSTEMS BIOLOGY; TRANSCRIPTOME; VACCINATION; VACCINES;

EID: 84941803445     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.072     Document Type: Article

References (86)

1. Behbehani A.M. The smallpox story: life and death of an old disease. Microbiol Rev 1983, 47:455-509.
2. Ehrenfeld E., Modlin J., Chumakov K. Future of polio vaccines. Expert Rev Vaccines 2009, 8:899-905.
3. Sasaki S., Jaimes M.C., Holmes T.H., Dekker C.L., Mahmood K., Kemble G.W., et al. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007, 81:215-228.
4. Barouch D.H., Michael N.L. Accelerating HIV-1 vaccine efficacy trials. Cell 2014, 159:969-972.
5. Funderud A., Aas-Hanssen K., Aksaas A.K., Hafte T.T., Corthay A., Munthe L.A., et al. Isoform-specific regulation of immune cell reactivity by the catalytic subunit of protein kinase A (PKA). Cell Signal 2009, 21:274-281.
6. Carpenter S., Ricci E.P., Mercier B.C., Moore M.J., Fitzgerald K.A. Post-transcriptional regulation of gene expression in innate immunity. Nat Rev Immunol 2014, 14:361-376.
7. Patti G.J., Yanes O., Siuzdak G. Innovation Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 2012, 13:263-269.
8. Kominsky D.J., Campbell E.L., Colgan S.P. Metabolic shifts in immunity and inflammation. J Immunol 2010, 184:4062-4068.
9. Bensinger S.J., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454:470-477.
10. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
11. Nakaya H.I., Li S., Pulendran B. Systems vaccinology: learning to compute the behavior of vaccine induced immunity. Wiley Interdiscip Rev Syst Biol Med 2012, 4:193-205.
12. Pulendran B., Li S., Nakaya H.I. Systems vaccinology. Immunity 2010, 33:516-529.
13. Pulendran B. Systems vaccinology: probing humanity's diverse immune systems with vaccines. Proc Natl Acad Sci USA 2014, 111:12300-12306.
14. Querec T.D., Akondy R.S., Lee E.K., Cao W., Nakaya H.I., Teuwen D., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009, 10:116-125.
15. Gaucher D., Therrien R., Kettaf N., Angermann B.R., Boucher G., Filali-Mouhim A., et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008, 205:3119-3131.
16. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol 2009, 9:741-747.
17. Pulendran B., Oh J.Z., Nakaya H.I., Ravindran R., Kazmin D.A. Immunity to viruses: learning from successful human vaccines. Immunol Rev 2013, 255:243-255.
18. Nakaya H.I., Wrammert J., Lee E.K., Racioppi L., Marie-Kunze S., Haining W.N., et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 2011, 12:786-795.
19. Bucasas K.L., Franco L.M., Shaw C.A., Bray M.S., Wells J.M., Nino D., et al. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J Infect Dis 2011, 203:921-929.
20. Vahey M.T., Wang Z., Kester K.E., Cummings J., Heppner D.G., Nau M.E., et al. Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine. J Infect Dis 2010, 201:580-589.
21. Reif D.M., Motsinger-Reif A.A., McKinney B.A., Rock M.T., Crowe J.E., Moore J.H. Integrated analysis of genetic and proteomic data identifies biomarkers associated with adverse events following smallpox vaccination. Genes Immun 2009, 10:112-119.
22. Zak D.E., Andersen-Nissen E., Peterson E.R., Sato A., Hamilton M.K., Borgerding J., et al. Merck Ad5/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci USA 2012, 109:E3503-E3512.
23. Obermoser G., Presnell S., Domico K., Xu H., Wang Y., Anguiano E., et al. Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity 2013, 38:831-844.
24. Tsang J.S., Schwartzberg P.L., Kotliarov Y., Biancotto A., Xie Z., Germain R.N., et al. Global analyses of human immune variation reveal baseline predictors of postvaccination responses. Cell 2014, 157:499-513.
25. Furman D., Jojic V., Kidd B., Shen-Orr S., Price J., Jarrell J., et al. Apoptosis and other immune biomarkers predict influenza vaccine responsiveness. Mol Syst Biol 2013, 9:659.
26. Chulay J.D., Schneider I., Cosgriff T.M., Hoffman S.L., Ballou W.R., Quakyi I.A., et al. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg 1986, 35:66-68.
27. Waddington C.S., Darton T.C., Jones C., Haworth K., Peters A., John T., et al. An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella typhi challenge delivered in sodium bicarbonate solution. Clin Infect Dis 2014, 58:1230-1240.
28. Marwick C. Volunteers in typhoid infection study will aid future vaccine development. JAMA 1998, 279:1423-1424.
29. Bodhidatta L., Pitisuttithum P., Chamnanchanant S., Chang K.T., Islam D., Bussaratid V., et al. Establishment of a Shigella sonnei human challenge model in Thailand. Vaccine 2012, 30:7040-7045.
30. Li S., Rouphael N., Duraisingham S., Romero-Steiner S., Presnell S., Davis C., et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol 2014, 15:195-204.
31. Gardner E.M., Gonzalez E.W., Nogusa S., Murasko D.M. Age-related changes in the immune response to influenza vaccination in a racially diverse, healthy elderly population. Vaccine 2006, 24:1609-1614.
32. Jackson L.A., Janoff E.N. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis 2008, 47:1328-1338.
33. Lutz W., Sanderson W., Scherbov S. The coming acceleration of global population ageing. Nature 2008, 451:716-719.
34. Duraisingham S.S., Rouphael N., Cavanagh M.M., Nakaya H.I., Goronzy J.J., Pulendran B. Systems biology of vaccination in the elderly. Curr Top Microbiol Immunol 2013, 363:117-142.
35. Sasaki S., Sullivan M., Narvaez C.F., Holmes T.H., Furman D., Zheng N.Y., et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest 2011, 121:3109-3119.
36. Wagar L.E., Gentleman B., Pircher H., McElhaney J.E., Watts T.H. Influenza-specific T cells from older people are enriched in the late effector subset and their presence inversely correlates with vaccine response. PLoS ONE 2011, 6(8):e23698.
37. Kang I.S., Hong M.S., Nolasco H., Park S.H., Dan J.M., Choi J.Y., et al. Age-associated change in the frequency of memory CD4(+) T cells impairs long term CD4(+) T cell responses to influenza vaccine. J Immunol 2004, 173:673-681.
38. Orru V., Steri M., Sole G., Sidore C., Virdis F., Dei M., et al. Genetic variants regulating immune cell levels in health and disease. Cell 2013, 155:242-256.
39. Kau A.L., Ahern P.P., Griffin N.W., Goodman A.L., Gordon J.I. Human nutrition, the gut microbiome and the immune system. Nature 2011, 474:327-336.
40. Hooper L.V., Littman D.R., Macpherson A.J. Interactions between the microbiota and the immune system. Science 2012, 336:1268-1273.
41. Padgett D.A., Glaser R. How stress influences the immune response. Trends Immunol 2003, 24:444-448.
42. Woods J.A., Vieira V.J., Keylock K.T. Exercise, inflammation, and innate immunity. Neurol Clin 2006, 24:585-599.
43. Brodin P., Jojic V., Gao T., Bhattacharya S., Angel C.J., Furman D., et al. Variation in the human immune system is largely driven by non-heritable influences. Cell 2015, 160:37-47.
44. O'Connor D., Pollard A.J. Characterizing vaccine responses using host genomic and transcriptomic analysis. Clin Infect Dis 2013, 57:860-869.
45. Gelder C.M., Lambkin R., Hart K.W., Fleming D., Williams O.M., Bunce M., et al. Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. J Infect Dis 2002, 185:114-117.
46. Moss A.J., Gaughran F.P., Karasu A., Gilbert A.S., Mann A.J., Gelder C.M., et al. Correlation between human leukocyte antigen class II alleles and HAI titers detected post-influenza vaccination. PLoS ONE 2013, 8(August (8)):e71376.
47. Poland G.A. Immunogenetic mechanisms of antibody response to measles vaccine: the role of the HLA genes. Vaccine 1999, 17:1719-1725.
48. Ovsyannikova I.G., Vierkant R.A., Pankratz V.S., Jacobson R.M., Poland G.A. Human leukocyte antigen genotypes in the genetic control of adaptive immune responses to smallpox vaccine. J Infect Dis 2011, 203:1546-1555.
49. Ovsyannikova I.G., Pankratz V.S., Salk H.M., Kennedy R.B., Poland G.A. HLA alleles associated with the adaptive immune response to smallpox vaccine: a replication study. Hum Genet 2014, 133:1083-1092.
50. Li Z.K., Nie J.J., Li J., Zhuang H. The effect of HLA on immunological response to hepatitis B vaccine in healthy people: a meta-analysis. Vaccine 2013, 31:4355-4361.
51. Lauterbach H., Ried C., Epstein A.L., Marconi P., Brocker T. Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity. J Gen Virol 2005, 86:2401-2410.
52. Sasaki S., He X.S., Holmes T.H., Dekker C.L., Kemble G.W., Arvin A.M., et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS ONE 2008, 3:e2975.
53. Plotkin S.A. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008, 47:401-409.
54. McElhaney J.E., Xie D., Hager W.D., Barry M.B., Wang Y., Kleppinger A., et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006, 176:6333-6339.
55. Pantaleo G., Koup R.A. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 2004, 10:806-810.
56. Hoft D.F. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 2008, 372:164-175.
57. Reyes-Sandoval A., Pearson F.E., Todryk S., Ewer K. Potency assays for novel T-cell-inducing vaccines against malaria. Curr Opin Mol Ther 2009, 11:72-80.
58. Stephenson I., Das R.G., Wood J.M., Katz J.M. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 2007, 25:4056-4063.
59. Frey S.E., Bernstein D.I., Brady R.C., Keitel W.A., Sahly H.E., Rouphael N.G., et al. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine 2015, 33:163-173.
60. Greenberg D.P., Robertson C.A., Noss M.J., Blatter M.M., Biedenbender R., Decker M.D. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 2013, 31:770-776.
61. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012, 366:1275-1286.
62. Olotu A., Clement F., Jongert E., Vekemans J., Njuguna P., Ndungu F.M., et al. Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01(E) in young children. PLoS ONE 2014, 9(December (12)):e115126.
63. Pulendran B., Miller J., Querec T.D., Akondy R., Moseley N., Laur O., et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 2008, 198:500-507.
64. Spitz F., Furlong E.E. Transcription factors: from enhancer binding to developmental control. Nat Rev Genet 2012, 13:613-626.
65. Leek J.T., Scharpf R.B., Bravo H.C., Simcha D., Langmead B., Johnson W.E., et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet 2010, 11:733-739.
66. Amit I., Garber M., Chevrier N., Leite A.P., Donner Y., Eisenhaure T., et al. Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. Science 2009, 326:257-263.
67. Kauffman R.E. Clinical trials in children: problems and pitfalls. Paediatr Drugs 2000, 2:411-418.
68. Johnstone I.M., Titterington D.M. Statistical challenges of high-dimensional data. Philos Trans A Math Phys Eng Sci 2009, 367:4237-4253.
69. Benjamini Y., Hochberg Y. Controlling the false discovery rate-a practical and powerful approach to multiple testing. J R Stat Soc B Met 1995, 57:289-300.
70. Storey J.D., Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003, 100:9440-9445.
71. Kotsiantis S.B., Zaharakis I.D., Pintelas P.E. Machine learning: a review of classification and combining techniques. Artif Intell Rev 2006, 26:159-190.
72. Breiman L. Random forests. Mach Learn 2001, 45:5-32.
73. Blum A.L., Langley P. Selection of relevant features and examples in machine learning. Artif Intell 1997, 97:245-271.
74. Inza I., Larranaga P., Etxeberria R., Sierra B. Feature subset selection by Bayesian network-based optimization. Artif Intell 2000, 123:157-184.
75. Bhattacharya S., Andorf S., Gomes L., Dunn P., Schaefer H., Pontius J., et al. ImmPort: disseminating data to the public for the future of immunology. Immunol Res 2014, 58:234-239.
76. Jeffery I.B., Higgins D.G., Culhane A.C. Comparison and evaluation of methods for generating differentially expressed gene lists from microarray data. BMC Bioinform 2006, 7:359.
77. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102:15545-15550.
78. Kanehisa M., Goto S., Hattori M., Aoki-Kinoshita K.F., Itoh M., Kawashima S., et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 2006, 34:D354-D357.
79. Vastrik I., D'Eustachio P., Schmidt E., Gopinath G., Croft D., de Bono B., et al. Reactome: a knowledge base of biologic pathways and processes (vol 8, pg 39, 2007). Genome Biol 2007, 8(3):R39.
80. Chaussabel D., Quinn C., Shen J., Patel P., Glaser C., Baldwin N., et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 2008, 29:150-164.
81. Chaussabel D., Baldwin N. Democratizing systems immunology with modular transcriptional repertoire analyses. Nat Rev Immunol 2014, 14:271-280.
82. Liberzon A., Subramanian A., Pinchback R., Thorvaldsdottir H., Tamayo P., Mesirov J.P. Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011, 27:1739-1740.
83. Ravindran R., Khan N., Nakaya H.I., Li S., Loebbermann J., Maddur M.S., et al. Vaccine activation of the nutrient sensor GCN2 in dendritic cells enhances antigen presentation. Science 2014, 343:313-317.
84. Anderson P., Kedersha N. Visibly stressed: the role of eIF2, TIA-1, and stress granules in protein translation. Cell Stress Chaperones 2002, 7:213-221.
85. Oh J.Z., Ravindran R., Chassaing B., Carvalho F.A., Maddur M.S., Bower M., et al. TLR5-mediated sensing of gut microbiota is necessary for antibody responses to seasonal influenza vaccination. Immunity 2014, 41:478-492.
86. Arumugam M., Raes J., Pelletier E., Le Paslier D., Yamada T., Mende D.R., et al. Enterotypes of the human gut microbiome. Nature 2011, 473:174-180.